Atacicept not checked
Vera Therapeutics, Inc. · VT-001
FollowEvery change as it happens, and a Monday email
Trials
4 active
5 in total · 4 in the EU
What this is
- How it works
- A decoy protein that soaks up a signal molecule before it can reach the body's cells.-cept: receptor molecules, native or modified WHO name stem
- How it’s given
- “Once weekly subcutaneous (SC) injections by prefilled syringe”In the company’s words, NCT04716231 on ClinicalTrials.gov
- Tested for
- Berger Disease (3 trials), IgA Nephropathy (IgAN) (2 trials), IgA Nephropathy, pMN, IgAN, Nephrotic Syndrome, MCD, FSGS and 1 more
- Main trialPhase 3
- “A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)”In the company’s words, NCT04716231 on ClinicalTrials.gov
- Other names
- VT-001
Other drugs for Berger Disease
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- SC0062Biocity Biopharmaceutics Co., Ltd. · Phase 3
- FelzartamabBiogen · Phase 3
- ZigakibartNovartis · Phase 3
- HRS-5965Hengrui · Phase 3
- IptacopanNovartis · Phase 3
Coming up2
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- 21 May 2031Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 13 NovCompletion date moved: 2026-09 to 2026-09-22 · ClinicalTrials.gov NCT07020923
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 15 May 2025 | Atacicept in Subjects With IgA Nephropathy | |
| Phase 2Active, not recruiting | 22 Sep 2026 | Monthly Dosing of Atacicept in IgAN | |
| Phase 2Recruiting | Nov 2027 | Atacicept in Multiple Glomerular Diseases | |
| Phase 2Enrolling by invitation | 21 May 2031 | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept | |
| Phase 3Withdrawn | 15 Mar 2026 | Atacicept in Subjects With Active Lupus Nephritis (COMPASS) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026